Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Riskbenzinga_article·21 hours agoENTX-4.67%
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE | ENTX Stock NewsStockTitan·1 day ago, 06:00 AMENTX-4.67%
Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquiredrttnews·2 days ago, 10:34 PMFBRX+1.00%TVGNW0.00%
OPK: Q2 2026 revenue rose and losses narrowed, with clinical and partnership progress highlightedQuartr·2 days ago, 03:11 PMOPK-1.68%ENTX-4.67%
Entera Bio surges 89% on $275M private placement for EB613 trialUS Stock Market Update·2 days ago, 12:00 PMENTX-4.67%
Entera Bio surges 51% on $275M private placement to fund Phase 3US Stock Market Update·Jul 27 at 08:51 AMENTX-4.67%
Entera Bio prices USD 275 million private placement at USD 2.04 per sharePUBT·Jul 27 at 07:32 AMENTX-4.67%
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga_article·Jul 16 at 07:05 AMATAI+0.14%DCOY+3.97%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jun 22 at 07:05 AMCRVO+1.61%CDT+1.65%
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga_article·Jun 22 at 12:05 PMATLN0.00%TNON-3.06%
Entera Bio shares are trading higher after the company announced the FDA accepted its plan to conduct a single, randomized, double-blind, placebo-controlled, Phase 3 trial to support a potential New Drug Application submission for EB613.benzinga_article·Jun 22 at 11:34 AMENTX-4.67%
